SUNPHARMA.NS

Of every 100 units of revenue, this much survives as profit.

Margins this wide usually mean real pricing power or a moat.

Profit from operations, before interest and tax, per 100 of revenue.

The operations themselves are comfortably profitable.

What is left of revenue after only the direct cost of the product.

Little marginal cost per sale, which is what lets software and pharma fund heavy R&D.

Borrowings measured against shareholder capital.

Comfortably financed.

Change in revenue against the same period last year.

A healthy expansion rate.

Change in earnings against the same period last year.

Profit is compounding at a good clip.

The share of earnings paid out as dividends.

Comfortably covered, with room to keep raising it.

Return earned per unit of risk taken.

Below 1 is the common case; return did not strongly outpace the volatility.

The share of trading days that closed higher.

Close to a coin flip, which is the norm — returns come from the size of moves, not their count.

You pay 36.73 for every 1 unit of annual earnings.

Above about 25 the market is paying up for expected growth.

Price against next year's *forecast* earnings.

A conventional range.

P/E divided by the growth rate — it asks whether the price is justified by the growth.

Between 1 and 2 price and growth are roughly in step.

Price against the accounting value of the company's net assets.

Normal for asset-light businesses, where the value sits in brands and software the balance sheet never records.

Price against revenue — usable when a company has no profit yet.

The price assumes today's revenue will convert into much more profit later.

Whole-company value, debt included, against cash earnings.

Expensive even before interest, tax and depreciation are considered.

Annual dividend as a percentage of the share price.

A small income component.

A 0–100 momentum gauge over the last 14 sessions.

The middle band, where most trading days sit.

How far the price typically swings over a year.

A typical range for an individual share.

How much the price moves relative to the wider market.

Tends to move less than the index, in both directions.

The worst peak-to-trough fall in the period measured.

No catastrophic fall in this window.

How far the mean analyst target sits above today's price.

Analysts see real room above today's price.